Plasma levels of adiponectin, a novel adipocyte-derived hormone, in sleep apnea

Robert Wolk, Anna Svatikova, Christy A. Nelson, Apoor S. Garni, Kogilan Govender, Mikolaj Winnicki, Virend Somers

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Objective: Obstructive sleep apnea (OSA) is associated with obesity, sympathetic activation, systemic inflammation, and cardiovascular morbidity. Obesity, β-adrenergic agonists, and inflammation are linked to decreased expression and/or secretion of an adipose tissue-derived antiatherogenic hormone, adiponectin. The purpose of the study was to investigate whether OSA affected plasma levels of adiponectin, which might help explain OSA-associated cardiovascular morbidity. Research Methods and Procedures: We randomly selected 68 otherwise healthy male subjects, either with moderate/ severe OSA [apnea-hypopnea index (AHI) ≥ 20; n = 35] or without OSA (AHI ≤ 5; n = 33). The diagnosis of OSA was made based on prospective full polysomnography. Adiponectin was measured before polysomnography between 8 and 10 PM. Results: AHI was higher in the OSA group (49.5 ± 4.4 vs. 2.9 ± 0.4 events/h; p < 0.001). OSA subjects were also more obese, with greater BMI (33 ± 1 vs. 30 ± 1; p = 0.016) and percentage body fat (29 ± 1% vs. 26 ± 1%; p = 0.030). Adiponectin levels were 7.67 ± 0.73 and 6.33 ± 0.51 μg/mL in the OSA and non-OS A groups, respectively, and this difference was significant in covariate analysis (taking into account age, hemodynamic characteristics, measures of body fat, and OSA severity) (p = 0.009). After excluding from both groups the subjects with extreme BMI, such that the OSA and non-OSA study cohorts had similar BMI and percentage body fat, subjects with OSA had significantly higher plasma adiponectin (8.49 ± 0.92 vs. 6.32 ± 0.55 μg/mL; p = 0.042), differences also evident in covariate analysis (p = 0.017). Discussion: Plasma adiponectin levels are elevated in otherwise healthy subjects with OSA. Therefore, low adiponectin is unlikely to explain the association between OSA and cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)186-190
Number of pages5
JournalObesity Research
Volume13
Issue number1
StatePublished - 2005

Fingerprint

sleep apnea
adiponectin
Adiponectin
Sleep Apnea Syndromes
Obstructive Sleep Apnea
adipocytes
Adipocytes
hormones
Hormones
apnea
Adipose Tissue
Apnea
body fat
Polysomnography
Healthy Volunteers
morbidity
Obesity
obesity
inflammation
Inflammation

Keywords

  • Adiponectin
  • Sleep apnea

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Public Health, Environmental and Occupational Health
  • Endocrinology
  • Food Science
  • Endocrinology, Diabetes and Metabolism

Cite this

Wolk, R., Svatikova, A., Nelson, C. A., Garni, A. S., Govender, K., Winnicki, M., & Somers, V. (2005). Plasma levels of adiponectin, a novel adipocyte-derived hormone, in sleep apnea. Obesity Research, 13(1), 186-190.

Plasma levels of adiponectin, a novel adipocyte-derived hormone, in sleep apnea. / Wolk, Robert; Svatikova, Anna; Nelson, Christy A.; Garni, Apoor S.; Govender, Kogilan; Winnicki, Mikolaj; Somers, Virend.

In: Obesity Research, Vol. 13, No. 1, 2005, p. 186-190.

Research output: Contribution to journalArticle

Wolk, R, Svatikova, A, Nelson, CA, Garni, AS, Govender, K, Winnicki, M & Somers, V 2005, 'Plasma levels of adiponectin, a novel adipocyte-derived hormone, in sleep apnea', Obesity Research, vol. 13, no. 1, pp. 186-190.
Wolk R, Svatikova A, Nelson CA, Garni AS, Govender K, Winnicki M et al. Plasma levels of adiponectin, a novel adipocyte-derived hormone, in sleep apnea. Obesity Research. 2005;13(1):186-190.
Wolk, Robert ; Svatikova, Anna ; Nelson, Christy A. ; Garni, Apoor S. ; Govender, Kogilan ; Winnicki, Mikolaj ; Somers, Virend. / Plasma levels of adiponectin, a novel adipocyte-derived hormone, in sleep apnea. In: Obesity Research. 2005 ; Vol. 13, No. 1. pp. 186-190.
@article{5d0e2220dcf3443c9a0b7251ab6a116b,
title = "Plasma levels of adiponectin, a novel adipocyte-derived hormone, in sleep apnea",
abstract = "Objective: Obstructive sleep apnea (OSA) is associated with obesity, sympathetic activation, systemic inflammation, and cardiovascular morbidity. Obesity, β-adrenergic agonists, and inflammation are linked to decreased expression and/or secretion of an adipose tissue-derived antiatherogenic hormone, adiponectin. The purpose of the study was to investigate whether OSA affected plasma levels of adiponectin, which might help explain OSA-associated cardiovascular morbidity. Research Methods and Procedures: We randomly selected 68 otherwise healthy male subjects, either with moderate/ severe OSA [apnea-hypopnea index (AHI) ≥ 20; n = 35] or without OSA (AHI ≤ 5; n = 33). The diagnosis of OSA was made based on prospective full polysomnography. Adiponectin was measured before polysomnography between 8 and 10 PM. Results: AHI was higher in the OSA group (49.5 ± 4.4 vs. 2.9 ± 0.4 events/h; p < 0.001). OSA subjects were also more obese, with greater BMI (33 ± 1 vs. 30 ± 1; p = 0.016) and percentage body fat (29 ± 1{\%} vs. 26 ± 1{\%}; p = 0.030). Adiponectin levels were 7.67 ± 0.73 and 6.33 ± 0.51 μg/mL in the OSA and non-OS A groups, respectively, and this difference was significant in covariate analysis (taking into account age, hemodynamic characteristics, measures of body fat, and OSA severity) (p = 0.009). After excluding from both groups the subjects with extreme BMI, such that the OSA and non-OSA study cohorts had similar BMI and percentage body fat, subjects with OSA had significantly higher plasma adiponectin (8.49 ± 0.92 vs. 6.32 ± 0.55 μg/mL; p = 0.042), differences also evident in covariate analysis (p = 0.017). Discussion: Plasma adiponectin levels are elevated in otherwise healthy subjects with OSA. Therefore, low adiponectin is unlikely to explain the association between OSA and cardiovascular disease.",
keywords = "Adiponectin, Sleep apnea",
author = "Robert Wolk and Anna Svatikova and Nelson, {Christy A.} and Garni, {Apoor S.} and Kogilan Govender and Mikolaj Winnicki and Virend Somers",
year = "2005",
language = "English (US)",
volume = "13",
pages = "186--190",
journal = "Obesity",
issn = "1930-7381",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Plasma levels of adiponectin, a novel adipocyte-derived hormone, in sleep apnea

AU - Wolk, Robert

AU - Svatikova, Anna

AU - Nelson, Christy A.

AU - Garni, Apoor S.

AU - Govender, Kogilan

AU - Winnicki, Mikolaj

AU - Somers, Virend

PY - 2005

Y1 - 2005

N2 - Objective: Obstructive sleep apnea (OSA) is associated with obesity, sympathetic activation, systemic inflammation, and cardiovascular morbidity. Obesity, β-adrenergic agonists, and inflammation are linked to decreased expression and/or secretion of an adipose tissue-derived antiatherogenic hormone, adiponectin. The purpose of the study was to investigate whether OSA affected plasma levels of adiponectin, which might help explain OSA-associated cardiovascular morbidity. Research Methods and Procedures: We randomly selected 68 otherwise healthy male subjects, either with moderate/ severe OSA [apnea-hypopnea index (AHI) ≥ 20; n = 35] or without OSA (AHI ≤ 5; n = 33). The diagnosis of OSA was made based on prospective full polysomnography. Adiponectin was measured before polysomnography between 8 and 10 PM. Results: AHI was higher in the OSA group (49.5 ± 4.4 vs. 2.9 ± 0.4 events/h; p < 0.001). OSA subjects were also more obese, with greater BMI (33 ± 1 vs. 30 ± 1; p = 0.016) and percentage body fat (29 ± 1% vs. 26 ± 1%; p = 0.030). Adiponectin levels were 7.67 ± 0.73 and 6.33 ± 0.51 μg/mL in the OSA and non-OS A groups, respectively, and this difference was significant in covariate analysis (taking into account age, hemodynamic characteristics, measures of body fat, and OSA severity) (p = 0.009). After excluding from both groups the subjects with extreme BMI, such that the OSA and non-OSA study cohorts had similar BMI and percentage body fat, subjects with OSA had significantly higher plasma adiponectin (8.49 ± 0.92 vs. 6.32 ± 0.55 μg/mL; p = 0.042), differences also evident in covariate analysis (p = 0.017). Discussion: Plasma adiponectin levels are elevated in otherwise healthy subjects with OSA. Therefore, low adiponectin is unlikely to explain the association between OSA and cardiovascular disease.

AB - Objective: Obstructive sleep apnea (OSA) is associated with obesity, sympathetic activation, systemic inflammation, and cardiovascular morbidity. Obesity, β-adrenergic agonists, and inflammation are linked to decreased expression and/or secretion of an adipose tissue-derived antiatherogenic hormone, adiponectin. The purpose of the study was to investigate whether OSA affected plasma levels of adiponectin, which might help explain OSA-associated cardiovascular morbidity. Research Methods and Procedures: We randomly selected 68 otherwise healthy male subjects, either with moderate/ severe OSA [apnea-hypopnea index (AHI) ≥ 20; n = 35] or without OSA (AHI ≤ 5; n = 33). The diagnosis of OSA was made based on prospective full polysomnography. Adiponectin was measured before polysomnography between 8 and 10 PM. Results: AHI was higher in the OSA group (49.5 ± 4.4 vs. 2.9 ± 0.4 events/h; p < 0.001). OSA subjects were also more obese, with greater BMI (33 ± 1 vs. 30 ± 1; p = 0.016) and percentage body fat (29 ± 1% vs. 26 ± 1%; p = 0.030). Adiponectin levels were 7.67 ± 0.73 and 6.33 ± 0.51 μg/mL in the OSA and non-OS A groups, respectively, and this difference was significant in covariate analysis (taking into account age, hemodynamic characteristics, measures of body fat, and OSA severity) (p = 0.009). After excluding from both groups the subjects with extreme BMI, such that the OSA and non-OSA study cohorts had similar BMI and percentage body fat, subjects with OSA had significantly higher plasma adiponectin (8.49 ± 0.92 vs. 6.32 ± 0.55 μg/mL; p = 0.042), differences also evident in covariate analysis (p = 0.017). Discussion: Plasma adiponectin levels are elevated in otherwise healthy subjects with OSA. Therefore, low adiponectin is unlikely to explain the association between OSA and cardiovascular disease.

KW - Adiponectin

KW - Sleep apnea

UR - http://www.scopus.com/inward/record.url?scp=20644454875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20644454875&partnerID=8YFLogxK

M3 - Article

C2 - 15761179

AN - SCOPUS:20644454875

VL - 13

SP - 186

EP - 190

JO - Obesity

JF - Obesity

SN - 1930-7381

IS - 1

ER -